Hjem › Mantelcellelymfom › Californien
Mantelcellelymfom kliniske forsøg i Californien
29 studier for Mantelcellelymfom søger deltagere på steder i Californien.
Byer i Californien
- Baldwin Park15 studier
- Mountain View7 studier
- Los Angeles7 studier
- San Diego5 studier
- San Francisco4 studier
- Irvine3 studier
Officiel studietekst (engelsk)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
RekruttererFase 3
Alder 60 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT05976763Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- University of California, Davis, Davis
- University of California, Los Angeles, Los Angeles
- University of California, San Diego, San Diego
- og 1 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06542250A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Stanford Cancer Center, Stanford
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06553872A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- City of Hope Comprehensive Cancer Center, Duarte
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07003295A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
RekruttererFase 1
Alder 18 til 85 · Alle køn · Opdateret 10. aug. 2026 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT07121946DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT05131022Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. jun. 2026 · NCT04545762Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- City of Hope Medical center, Duarte
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. apr. 2026 · NCT03523975Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. apr. 2026 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- og 1 flere
RekruttererFase 1/2
Alder 12 til 95 · Alle køn · Opdateret 15. apr. 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. mar. 2026 · NCT04830137Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT06572618Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 23. feb. 2026 · NCT05432635Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 5. jan. 2026 · NCT06054776AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. dec. 2025 · NCT05602363BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 20. nov. 2025 · NCT05370430SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- og 3 flere
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Stanford Cancer Center, Palo Alto
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 22. aug. 2024 · NCT05255354Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.